Board member
Education: BSc in Economics & Business Administration and MSc in Business Economics & Auditing, Copenhagen Business School.
Background: +20 years of experience within the global pharma industry across different functional areas such as Business Development, Corporate Strategy, Finance and Auditing. Served in several finance leadership positions at Roche from 2000 and until 2011, where he joined Roche Strategic Partnering. From 2017 he was promoted to Global Head of Roche Strategic Partnering and a member of the Roche Pharma Late Stage Portfolio Committee. In 2019, Keld joined Lundbeck as EVP and Chief Business Officer, responsible for Corporate Strategy and Business Development. During the past +10 years in BD, Keld has executed M&A’s and partnering deals worth >10 bio USD
Other ongoing assignments: SVP & Chief Business Officer of Lundbeck A/S
Independence: Independent in relation to both the Company and executive management.
Scandion Oncology shares and warrants:
312,500 shares, 234,375 TO2 warrants, 78,125 TO3 warrants and 64,271 Incentive warrants.